Earnings Updates, In Brief: Vitae, OncoGenex, Cara
Executive Summary
Vitae and partner Boehringer Ingelheim to start over in Alzheimer’s with new compound, shelving lead drug due to skin reactions. OncoGenex sees subgroup data providing a potential niche indication for custirsen, while Cara is ready to begin Phase III with its intravenous candidate for post-surgical acute pain.
You may also be interested in...
Autoimmune RORγt Program May Portend Change Of Direction For Vitae
The drug-discovery specialist is mulling several potential partners for its ROR gamma t inhibitor program, which has potential in autoimmune indications. Two cash-generating deals with Boehringer Ingelheim have made the clinical-stage company self-sufficient for nearly a decade.
OncoGenex/Teva Alter Late-Stage Custirsen Program
Teva and OncoGenex announced changes to the Phase III program of their prostate cancer drug custirsen on the heels of positive data from a competitor.
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.